Compare Fabrinet (FN) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Humana Inc — how do they compare? Fabrinet trades at $486.28 (market cap $17.46B), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 2.7× Fabrinet's market cap, and Humana Inc pays a 0.91% dividend while Fabrinet pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Humana Inc for 51 Days on average.
| FN | HUM | |
|---|---|---|
Market Cap | $17.46B | $46.49B |
Volume | 1,199,886 | 2,567,704 |
Sector | Technology | Health |
52-Week High | $746.47 | $431.03 |
52-Week Low | $361.94 | $163.67 |
Typical Hold Time | 30 Days | 51 Days |
Enterprise Value | $16.59B | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $487.33, down 2.14% on the day, yet maintains a bullish technical stance with strong analyst support. The stock shows robust fundamentals, with Q2 2026 EPS of $4.10 beating estimates and revenue growth accelerating to $4.6B in 2026. Positive sentiment is driven by surging AI data-center demand, though the stock faces near-term pressure from high valuations and capital expenditure concerns.
Outlook remains positive given FN's strategic position in AI infrastructure and capacity expansion, with a consensus price target of $769.50 implying significant upside. Key risks include customer concentration, margin pressure from spending, and sensitivity to tech sector volatility. The combination of strong earnings momentum and Wall Street optimism supports a constructive view for long-term investors.
Humana (HUM) trades at $387.12, down 2.37% today, with a bullish technical outlook supported by moving averages and strong institutional interest. The company shows steady revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent analyst upgrades and a $460.74 consensus price target suggest upside potential, while Medicare Advantage plan changes and fiduciary scrutiny present near-term headwinds.
The stock offers value with a low P/S ratio of 0.32x and consistent earnings beats, but faces margin pressure and regulatory risks. Institutional accumulation and positive technicals support a constructive outlook, though investors should monitor enrollment trends and cost management execution for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
